BIO vs CYTK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Bio-Rad Laboratories has a Piotroski F-Score of 6/9, indicating stable financial health, but lacks an Altman Z-Score for distress risk assessment. The company shows strong gross margins and solid earnings surprises historically, yet faces near-term headwinds with negative profit margins, declining EPS Q/Q, and weak revenue growth. Valuation metrics suggest premium pricing with a Forward P/E of 29.22 and Price/Sales of 3.13, while insider activity is bearish and analyst recommendation remains 'buy' with a $348 target. Despite solid balance sheet strength, profitability deterioration and lack of dividend or intrinsic value clarity limit upside conviction.
CYTK shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 5/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BIO vs CYTK: Head-to-Head Comparison
This page compares Bio-Rad Laboratories, Inc. (BIO) and Cytokinetics, Incorporated (CYTK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.